Socioeconomic and Clinical Factors Influence the Interval Between Positive Prostate Biopsy and Radical Prostatectomy

被引:18
|
作者
Pitman, Max [1 ]
Korets, Ruslan [1 ]
Kates, Max [1 ]
Hruby, Gregory W. [1 ]
McKiernan, James M. [1 ]
机构
[1] Columbia Univ Coll Phys & Surg, Dept Urol, New York, NY 10032 USA
关键词
RACIAL-DIFFERENCES; CANCER-PATIENTS; EQUAL-ACCESS; LOW-INCOME; OUTCOMES; MEN; RISK; POPULATION; MARRIAGE; SURVIVAL;
D O I
10.1016/j.urology.2012.01.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To examine socioeconomic and clinical factors that may predict a longer interval between prostate biopsy and radical prostatectomy (RP). METHODS The Columbia University Urologic Oncology Database was queried for patients who underwent RP from 1990-2010. Time to surgery (TTS) was defined as the period between the most recent positive prostate biopsy and date of surgery. Clinical factors examined included: age, D'Amico risk group, year of surgery, body mass index, and comorbidities. Socioeconomic factors included race/ethnicity, relationship status, income, and distance to treatment center. The relationship between clinical/socioeconomic factors and TTS was evaluated using univariate and multivariate regression models. RESULTS Two-thousand five-hundred seventy-three patients were included in the analysis. Median TTS was 48 days (IQR 35-70, range 43-1103), and 71% of patients underwent RP within 60 days after the most recent positive biopsy. On multivariate analysis, living further from the medical center was associated with shorter TTS (P = .01), whereas more recent year of surgery (P = .01), comorbid cardiovascular disease (P = .007), African-American (P = .005) or Hispanic race (P = .005), divorced relationship status (P = .01), and lower income (P = .003) were all associated with longer TTS. CONCLUSION Patients often experience widely variable intervals between the diagnosis and treatment of localized prostate cancer. Longer intervals before surgery may point to disparities in access to prostate cancer care, and not increased decision-making time by the patient. UROLOGY 80: 1027-1032, 2012. (C) 2012 Published by Elsevier Inc.
引用
收藏
页码:1027 / 1032
页数:6
相关论文
共 50 条
  • [31] The influence of hepatic function on prostate cancer outcomes after radical prostatectomy
    Banez, L. L.
    Loftis, R. M.
    Freedland, S. J.
    Presti, J. C., Jr.
    Aronson, W. J.
    Amling, C. L.
    Kane, C. J.
    Terris, M. K.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (02) : 173 - 177
  • [32] Socioeconomic position and mortality among patients with prostate cancer: influence of mediating factors
    Larsen, Signe Benzon
    Brasso, Klaus
    Christensen, Jane
    Johansen, Christoffer
    Tjonneland, Anne
    Friis, Soren
    Iversen, Peter
    Dalton, Susanne Oksbjerg
    ACTA ONCOLOGICA, 2017, 56 (04) : 563 - 568
  • [33] The Impact of Clinical Stage on Prostate Cancer Survival Following Radical Prostatectomy
    Tollefson, Matthew K.
    Karnes, R. Jeffrey
    Rangel, Laureano J.
    Bergstralh, Eric J.
    Boorjian, Stephen A.
    JOURNAL OF UROLOGY, 2013, 189 (05) : 1707 - 1712
  • [34] Discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy: Implications for focal therapy
    Sinnott, Michael
    Falzarano, Sara M.
    Hernandez, Adrian V.
    Jones, J. Stephen
    Klein, Eric A.
    Zhou, Ming
    Magi-Galluzzi, Cristina
    PROSTATE, 2012, 72 (11) : 1179 - 1186
  • [35] The transverse and vertical distribution of prostate cancer in biopsy and radical prostatectomy specimens
    Mai, Zhipeng
    Zhou, Zhien
    Yan, Weigang
    Xiao, Yu
    Zhou, Yi
    Liang, Zhiyong
    Ji, Zhigang
    Li, Hanzhong
    BMC CANCER, 2018, 18
  • [36] Comparison of TRUS and combined MRI-targeted plus systematic prostate biopsy for the concordance between biopsy and radical prostatectomy pathology
    Aslan, Guven
    Celik, Serdar
    Sozen, Sinan
    Akdogan, Bulent
    Izol, Volkan
    Bilen, Cenk Yucel
    Sahin, Bahadir
    Turkeri, Levent
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (03)
  • [37] Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer
    Preisser, Felix
    Wuernschimmel, Christoph
    Pose, Randi M.
    Heinze, Alexander
    Steuber, Thomas
    Michl, Uwe
    Salomon, Georg
    Mandel, Philipp
    Graefen, Markus
    Tilki, Derya
    PROSTATE, 2022, 82 (02) : 254 - 259
  • [38] Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer
    Preisser, Felix
    Mazzone, Elio
    Nazzani, Sebastiano
    Bandini, Marco
    Tian, Zhe
    Marchioni, Michele
    Steuber, Thomas
    Saad, Fred
    Montorsi, Francesco
    Shariat, Shahrokh F.
    Huland, Hartwig
    Graefen, Markus
    Tilki, Derya
    Karakiewicz, Pierre, I
    EUROPEAN UROLOGY, 2018, 74 (06) : 693 - 696
  • [39] Assessment of positive surgical margins in the management of patients after radical prostatectomy for pT2 prostate cancer
    Saier, E.
    Pinar, U.
    De la Taille, A.
    Irani, J.
    Salomon, L.
    PROGRES EN UROLOGIE, 2022, 32 (05): : 354 - 362
  • [40] Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer
    Engel, Jutta
    Bastian, Patrick J.
    Baur, Helmut
    Beer, Volker
    Chaussy, Christian
    Gschwend, Juergen E.
    Oberneder, Ralph
    Rothenberger, Karl H.
    Stief, Christian G.
    Hoelzel, Dieter
    EUROPEAN UROLOGY, 2010, 57 (05) : 754 - 761